Kite Pharma, a Gilead Company, has leased a new 177,000 square-foot facility in the Netherlands for manufacturing cell therapies. The 117,000 square-foot site in Hoofddorp will allow Kite to manufacture and deliver its cell therapies to people living with cancer in Europe. The plant will employ 300 workers when fully operational in 2020.   The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that...